Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS

NCT01159028 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Adult Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Ph1 Positive CML

Interventions

DRUG: BP1001
DRUG: BP1001 in combination with LDAC

Sponsor

Bio-Path Holdings, Inc.